Morbidity of Vestibular Schwannomas as Documented by Treating Providers

Miriam A Nuno, Beatrice Ugiliweneza, Maxwell Boakye, Ashkan Monfared

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Characterize the morbidity associated with vestibular schwannoma (VS) as documented by treating providers. STUDY DESIGN: Retrospective analysis of the MarketScan database. SETTING: MarketScan database. SUBJECTS AND METHODS: A study of morbidity in VS patients who underwent treatment between 2002 and 2012 was conducted. A detailed account of morbidity at multiple time points before and after treatment was described. RESULTS: Of 3,355 patients treated for VS, 2,029 (60.5%) underwent surgery and 1,326 (39.5%) radiation. The average (SD) age of diagnosis was 52.5 (12.1) years. Patients were followed for a mean (SD) of 29.1 (24.2) months before and 39.2 (30.5) months after treatment. Hearing loss (65.4%), vertigo (28.0%), tinnitus (24.7%), and headache (15.2%) were the most documented symptoms at 6 months before treatment. At this juncture, higher rates of hearing loss (71.6 versus 58.6%, p < 0.0001), vertigo (32.3 versus 21.4%, p<0.0001), and tinnitus (26.9 versus 21.5%, p=0.0004) were reported for the surgery cohort. At 6 months posttreatment, surgery cohort were reported to have higher rates of hearing loss (OR 2.15, 95% CI: 1.82-2.52), vertigo (OR 1.56, 95% CI: 1.23-1.96), balance (OR 4.17, 95% CI: 3.03-5.56), facial weakness (OR 10.0, 95% CI: 6.67-14.29), headache (OR 1.56, 95% CI: 1.23-1.96), fatigue (OR 2.22, 95% CI: 1.19-4.17), and swallowing difficulties (OR 2.33, 95% CI: 1.43-3.70) compared with radiosurgery group. Surgery patients also experienced more treatment-related complications than the radiation (28.5 versus 2.6%, p<0.0001) cohort. CONCLUSIONS: Patients who eventually underwent surgery were reported by their providers to have higher morbidity before and after treatment.

Fingerprint

Acoustic Neuroma
Morbidity
Vertigo
Hearing Loss
Tinnitus
Headache
Therapeutics
Databases
Radiation
Radiosurgery
Deglutition
Fatigue

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Sensory Systems
  • Clinical Neurology

Cite this

@article{c1e7aa43dbb54377a59652db73357778,
title = "Morbidity of Vestibular Schwannomas as Documented by Treating Providers",
abstract = "OBJECTIVE: Characterize the morbidity associated with vestibular schwannoma (VS) as documented by treating providers. STUDY DESIGN: Retrospective analysis of the MarketScan database. SETTING: MarketScan database. SUBJECTS AND METHODS: A study of morbidity in VS patients who underwent treatment between 2002 and 2012 was conducted. A detailed account of morbidity at multiple time points before and after treatment was described. RESULTS: Of 3,355 patients treated for VS, 2,029 (60.5{\%}) underwent surgery and 1,326 (39.5{\%}) radiation. The average (SD) age of diagnosis was 52.5 (12.1) years. Patients were followed for a mean (SD) of 29.1 (24.2) months before and 39.2 (30.5) months after treatment. Hearing loss (65.4{\%}), vertigo (28.0{\%}), tinnitus (24.7{\%}), and headache (15.2{\%}) were the most documented symptoms at 6 months before treatment. At this juncture, higher rates of hearing loss (71.6 versus 58.6{\%}, p < 0.0001), vertigo (32.3 versus 21.4{\%}, p<0.0001), and tinnitus (26.9 versus 21.5{\%}, p=0.0004) were reported for the surgery cohort. At 6 months posttreatment, surgery cohort were reported to have higher rates of hearing loss (OR 2.15, 95{\%} CI: 1.82-2.52), vertigo (OR 1.56, 95{\%} CI: 1.23-1.96), balance (OR 4.17, 95{\%} CI: 3.03-5.56), facial weakness (OR 10.0, 95{\%} CI: 6.67-14.29), headache (OR 1.56, 95{\%} CI: 1.23-1.96), fatigue (OR 2.22, 95{\%} CI: 1.19-4.17), and swallowing difficulties (OR 2.33, 95{\%} CI: 1.43-3.70) compared with radiosurgery group. Surgery patients also experienced more treatment-related complications than the radiation (28.5 versus 2.6{\%}, p<0.0001) cohort. CONCLUSIONS: Patients who eventually underwent surgery were reported by their providers to have higher morbidity before and after treatment.",
author = "Nuno, {Miriam A} and Beatrice Ugiliweneza and Maxwell Boakye and Ashkan Monfared",
year = "2019",
month = "2",
day = "1",
doi = "10.1097/MAO.0000000000002099",
language = "English (US)",
volume = "40",
pages = "e142--e149",
journal = "Otology and Neurotology",
issn = "1531-7129",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Morbidity of Vestibular Schwannomas as Documented by Treating Providers

AU - Nuno, Miriam A

AU - Ugiliweneza, Beatrice

AU - Boakye, Maxwell

AU - Monfared, Ashkan

PY - 2019/2/1

Y1 - 2019/2/1

N2 - OBJECTIVE: Characterize the morbidity associated with vestibular schwannoma (VS) as documented by treating providers. STUDY DESIGN: Retrospective analysis of the MarketScan database. SETTING: MarketScan database. SUBJECTS AND METHODS: A study of morbidity in VS patients who underwent treatment between 2002 and 2012 was conducted. A detailed account of morbidity at multiple time points before and after treatment was described. RESULTS: Of 3,355 patients treated for VS, 2,029 (60.5%) underwent surgery and 1,326 (39.5%) radiation. The average (SD) age of diagnosis was 52.5 (12.1) years. Patients were followed for a mean (SD) of 29.1 (24.2) months before and 39.2 (30.5) months after treatment. Hearing loss (65.4%), vertigo (28.0%), tinnitus (24.7%), and headache (15.2%) were the most documented symptoms at 6 months before treatment. At this juncture, higher rates of hearing loss (71.6 versus 58.6%, p < 0.0001), vertigo (32.3 versus 21.4%, p<0.0001), and tinnitus (26.9 versus 21.5%, p=0.0004) were reported for the surgery cohort. At 6 months posttreatment, surgery cohort were reported to have higher rates of hearing loss (OR 2.15, 95% CI: 1.82-2.52), vertigo (OR 1.56, 95% CI: 1.23-1.96), balance (OR 4.17, 95% CI: 3.03-5.56), facial weakness (OR 10.0, 95% CI: 6.67-14.29), headache (OR 1.56, 95% CI: 1.23-1.96), fatigue (OR 2.22, 95% CI: 1.19-4.17), and swallowing difficulties (OR 2.33, 95% CI: 1.43-3.70) compared with radiosurgery group. Surgery patients also experienced more treatment-related complications than the radiation (28.5 versus 2.6%, p<0.0001) cohort. CONCLUSIONS: Patients who eventually underwent surgery were reported by their providers to have higher morbidity before and after treatment.

AB - OBJECTIVE: Characterize the morbidity associated with vestibular schwannoma (VS) as documented by treating providers. STUDY DESIGN: Retrospective analysis of the MarketScan database. SETTING: MarketScan database. SUBJECTS AND METHODS: A study of morbidity in VS patients who underwent treatment between 2002 and 2012 was conducted. A detailed account of morbidity at multiple time points before and after treatment was described. RESULTS: Of 3,355 patients treated for VS, 2,029 (60.5%) underwent surgery and 1,326 (39.5%) radiation. The average (SD) age of diagnosis was 52.5 (12.1) years. Patients were followed for a mean (SD) of 29.1 (24.2) months before and 39.2 (30.5) months after treatment. Hearing loss (65.4%), vertigo (28.0%), tinnitus (24.7%), and headache (15.2%) were the most documented symptoms at 6 months before treatment. At this juncture, higher rates of hearing loss (71.6 versus 58.6%, p < 0.0001), vertigo (32.3 versus 21.4%, p<0.0001), and tinnitus (26.9 versus 21.5%, p=0.0004) were reported for the surgery cohort. At 6 months posttreatment, surgery cohort were reported to have higher rates of hearing loss (OR 2.15, 95% CI: 1.82-2.52), vertigo (OR 1.56, 95% CI: 1.23-1.96), balance (OR 4.17, 95% CI: 3.03-5.56), facial weakness (OR 10.0, 95% CI: 6.67-14.29), headache (OR 1.56, 95% CI: 1.23-1.96), fatigue (OR 2.22, 95% CI: 1.19-4.17), and swallowing difficulties (OR 2.33, 95% CI: 1.43-3.70) compared with radiosurgery group. Surgery patients also experienced more treatment-related complications than the radiation (28.5 versus 2.6%, p<0.0001) cohort. CONCLUSIONS: Patients who eventually underwent surgery were reported by their providers to have higher morbidity before and after treatment.

UR - http://www.scopus.com/inward/record.url?scp=85059795593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059795593&partnerID=8YFLogxK

U2 - 10.1097/MAO.0000000000002099

DO - 10.1097/MAO.0000000000002099

M3 - Article

C2 - 30624406

AN - SCOPUS:85059795593

VL - 40

SP - e142-e149

JO - Otology and Neurotology

JF - Otology and Neurotology

SN - 1531-7129

IS - 2

ER -